New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target ...

DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections ...

NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human ...

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie (ABBV)'s growing ADC portfolio designed to target ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Avacta Group plc ( (GB:AVCT)) has ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, ...

BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields ...

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium Groundbreaking oncology development with the first ...

– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today ...

PLAINSBORO, N.J., and BAGSVÆRD, Denmark, Oct. 20, 2025 /PRNewswire/ -- Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be presented at ...